INIS
patients
100%
cancer
100%
recommendations
100%
molecules
100%
lung cells
100%
anticoagulants
100%
drugs
90%
interactions
72%
risks
18%
reviews
18%
administration
18%
doses
9%
therapy
9%
increasing
9%
information
9%
comparative evaluations
9%
usa
9%
interventions
9%
toxicity
9%
europe
9%
classification
9%
adjustments
9%
medicines
9%
food and drug administration
9%
prophylaxis
9%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
100%
Direct Oral Anticoagulants
100%
Small Molecule Inhibitors
100%
Drug Interactions
88%
Europe
11%
Patients at Risk
11%
European Medicines Agency
11%
Non-small Cell Lung Cancer Patients
11%
Anticoagulant Therapy
11%
Anticoagulants
11%
Bleeding
11%
Thromboembolism
11%
Clot
11%
Dose Adjustment
11%
U.S. Food
11%
Edoxaban
11%
Interaction Characteristics
11%
Potency Classification
11%
Medicine and Dentistry
Lung Cancer
100%
Direct Oral Anticoagulant
100%
Drug Interaction
88%
Medicine
11%
Bleeding
11%
Anticoagulant Therapy
11%
Thromboembolism
11%
Anticoagulant
11%
Edoxaban
11%
Pharmacology, Toxicology and Pharmaceutical Science
Lung Cancer
100%
Direct Oral Anticoagulant
100%
Drug-Drug Interaction
88%
Anticoagulant Agent
22%
Bleeding
11%
Thromboembolism
11%
Edoxaban
11%
Biochemistry, Genetics and Molecular Biology
Small Molecule
100%
Drug Interaction
100%